Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
BriaCell Therapeutics Corp. Warrant (BCTXZ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/18/2025: BCTXZ (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -35.56% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/18/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.91 - 1.51 | Updated Date 04/29/2025 |
52 Weeks Range 0.91 - 1.51 | Updated Date 04/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
BriaCell Therapeutics Corp. Warrant
Company Overview
History and Background
BriaCell Therapeutics Corp. Warrant does not have a distinct history or founding year as it represents a right to purchase shares of BriaCell Therapeutics Corp. These warrants are typically issued by the company itself or attached to other securities to incentivize investment. Significant milestones for the warrants would be tied to the overall performance and corporate actions of BriaCell Therapeutics Corp.
Core Business Areas
- Oncology Drug Development: BriaCell Therapeutics Corp. is focused on developing and commercializing personalized immunotherapies for cancer. Their core technology aims to retrain the patient's immune system to recognize and attack cancer cells.
Leadership and Structure
The leadership and structure of BriaCell Therapeutics Corp. Warrant are intrinsically linked to the parent company, BriaCell Therapeutics Corp. Information on their leadership team can be found on the parent company's official website and SEC filings.
Top Products and Market Share
Key Offerings
- BRIA 88 (Cancer Therapy): BRIA 88 is BriaCell's lead candidate, a personalized immunotherapy designed to treat various solid tumors. It aims to leverage the patient's own immune system. Market share data for this nascent therapy is not yet applicable. Key competitors include companies developing other forms of immunotherapy and targeted cancer therapies such as Bristol Myers Squibb (Opdivo, Yervoy), Merck (Keytruda), and Pfizer (Ibrance).
Market Dynamics
Industry Overview
The oncology drug development industry is highly competitive and capital-intensive, driven by significant unmet medical needs and advancements in biotechnology. The immunotherapy segment, in particular, is experiencing rapid growth and innovation.
Positioning
BriaCell Therapeutics Corp. is positioned as a novel immunotherapy developer focusing on personalized treatments. Their unique approach aims to differentiate them in a crowded market. Their competitive advantage lies in their personalized cell therapy platform.
Total Addressable Market (TAM)
The TAM for cancer therapeutics is vast and continually growing. For immunotherapies, estimates vary widely but are in the hundreds of billions of dollars globally. BriaCell Therapeutics Corp. is targeting specific cancer types within this broad market.
Upturn SWOT Analysis
Strengths
- Innovative personalized immunotherapy platform.
- Focus on a significant unmet medical need in oncology.
- Potential for novel treatment mechanisms.
Weaknesses
- Early-stage drug development with inherent risks.
- Limited clinical data available to date.
- Dependence on successful clinical trials and regulatory approvals.
- Limited financial resources compared to larger pharmaceutical companies.
Opportunities
- Growing market for immunotherapies.
- Potential for strategic partnerships and collaborations.
- Expansion into various cancer indications.
- Advancements in precision medicine and genetic sequencing.
Threats
- High failure rates in drug development.
- Intense competition from established and emerging biotech companies.
- Regulatory hurdles and lengthy approval processes.
- Reimbursement challenges for novel therapies.
- Changes in healthcare policy.
Competitors and Market Share
Key Competitors
- Bristol Myers Squibb (BMY)
- Merck & Co., Inc. (MRK)
- Pfizer Inc. (PFE)
- Moderna, Inc. (MRNA)
Competitive Landscape
BriaCell Therapeutics Corp. is a small player in a highly competitive landscape dominated by large pharmaceutical companies with extensive R&D budgets and established market presence. BriaCell's advantage lies in its specialized focus on personalized immunotherapy, which may offer a niche benefit. However, it faces challenges in scaling operations, funding extensive clinical trials, and competing for market share against established blockbusters.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for BriaCell Therapeutics Corp. Warrant is tied to the historical performance of BriaCell Therapeutics Corp. (BCTX) stock. As an early-stage biotech, BCTX's growth trajectory has likely been volatile, driven by clinical trial progress and funding rounds.
Future Projections: Future projections for BriaCell Therapeutics Corp. Warrant depend heavily on the successful development and commercialization of BriaCell Therapeutics Corp.'s (BCTX) pipeline. Analyst estimates for BCTX would be indicative of potential future stock performance.
Recent Initiatives: Recent initiatives for BriaCell Therapeutics Corp. would likely include progress in clinical trials for their lead candidates, potential regulatory filings, and ongoing fundraising efforts to support R&D.
Summary
BriaCell Therapeutics Corp. Warrant is tied to the performance of BriaCell Therapeutics Corp., an early-stage oncology immunotherapy company. The company shows promise with its innovative personalized approach but faces significant risks inherent in drug development, intense competition, and the need for substantial funding. Its success hinges on the successful progression of its clinical pipeline through regulatory approvals.
Similar Stocks
Sources and Disclaimers
Data Sources:
- BriaCell Therapeutics Corp. Investor Relations
- SEC Filings (10-K, 10-Q)
- Financial News Outlets
- Industry Research Reports
Disclaimers:
This JSON output is for informational purposes only and does not constitute financial advice. Warrant performance is directly linked to the underlying stock's performance and is subject to significant risk. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BriaCell Therapeutics Corp. Warrant
Exchange NASDAQ | Headquaters West Vancouver, BC, Canada | ||
IPO Launch date 2025-04-25 | CEO, President & Director Dr. William V. Williams FCPA, M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://briacell.com |
Full time employees - | Website https://briacell.com | ||
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.